Parkinson's Disease: What It Is, What's FDA-Approved, and What GLP-1s, TRT, and Exercise Actually Do

Parkinson's disease attracts a lot of hopeful claims — about peptides, hormones, and lifestyle interventions that might slow or modify it. Some of that hope is genuinely earned by real research. Some of it is preclinical promise that didn't survive contact with a real clinical trial. Here's what the evidence actually shows, category by category. What Parkinson's Disease Actually Is Parkinson's disease is a progressive neurodegenerative condition caused primarily by the loss of dopamine-producing neurons in a brain region called the substantia nigra. The hallmark microscopic finding is Lewy bodies — abnormal clumps of a protein called alpha-synuclein that accumulate inside neurons. The classic motor symptoms — tremor (usually starting on one side), rigidity, bradykinesia (slowness of movement), and postural instability — result from the resulting dopamine deficit. Non-motor symptoms are just as significant and often precede the motor symptoms by years: sleep disturbances, loss of sense of smell, constipation, depression, and eventually cognitive changes in many patients. What's Actually FDA-Approved Right Now The medication landscape has genuinely expanded in the last two years, beyond the classic options. Current FDA-approved treatments include: Levodopa/carbidopa — still the foundational, most effective treatment, available as immediate-release (Sinemet), extended-release (Rytary), and a newer 2024-approved dual-release capsule (Crexont) designed to extend "on" time with less frequent dosing. Duopa/Duodopa delivers the same combination as a continuous intestinal gel infusion for advanced disease. Dopamine agonists — pramipexole, ropinirole, and rotigotine (transdermal patch), which directly stimulate dopamine receptors. MAO-B inhibitors — selegiline, rasagiline, and safinamide (Xadago), which slow the breakdown of dopamine in the brain. COMT inhibitors — entacapone and opicapone (Ongentys), used alongside levodopa to extend its effect. Adenosine A2A antagonist — istradefylline (Nourianz), a newer mechanism used as an add-on therapy. Continuous infusion therapies — two genuinely new delivery innovations reached approval recently: Vyalev (foscarbidopa/foslevodopa), a 24-hour subcutaneous levodopa infusion approved in 2024, and Onapgo, a continuous subcutaneous apomorphine infusion approved in early 2025 — both aimed at smoothing out the motor fluctuations that oral medication alone struggles to control in advanced disease. Inhaled levodopa (Inbrija) — for managing sudden "off" episodes between regular doses. Deep brain stimulation (DBS) — not a medication, but an FDA-approved device therapy, with adaptive DBS (which adjusts stimulation in real time based on brain signals) now available for appropriate candidates. In the pipeline: tavapadon, a selective dopamine agonist with an NDA submitted to the FDA in September 2025, and bemdaneprocel, a stem-cell-derived dopamine neuron replacement therapy currently in Phase 3 trials — a fundamentally different approach aimed at replacing lost cells rather than managing symptoms. Peptides for Parkinson's: The Honest Current State There is no peptide currently FDA-approved specifically for Parkinson's disease. The peptide class with by far the most research interest and clinical trial investment is GLP-1 receptor agonists — covered in detail below — precisely because they're already approved diabetes and weight-management drugs with a plausible neuroprotective mechanism, making them easier to test in PD than a novel compound starting from scratch. GLP-1 Receptor Agonists and Parkinson's: Promising Mechanism, Disappointing Trial Results So Far This is the single most actively researched peptide-adjacent question in PD right now, and it's worth understanding both why the excitement was real and why the most rigorous recent data hasn't confirmed it. According to PubMed, a 2026 review found that GLP-1 receptor agonists show consistent neuroprotective effects in preclinical studies — preserving dopaminergic neurons, reducing alpha-synuclein aggregation, and improving motor function in animal models, working through effects on neuroinflammation, mitochondrial function, and oxidative stress ([Dahshan et al., Clinical Parkinsonism & Related Disorders, 2026, PMID: 42328044](https://doi.org/10.1016/j.prdoa.2026.100461)). Earlier, smaller randomized trials of exenatide and lixisenatide had indeed suggested modest motor benefits and possible disease-modifying effects, which is where a lot of the public optimism about GLP-1s and PD originated. The more rigorous, larger data since then has been considerably less encouraging. According to PubMed, a systematic review and meta-analysis of four randomized placebo-controlled trials covering 667 PD patients — including the Phase III Exenatide-PD3 trial — found no significant difference between GLP-1RA and placebo groups on the standard motor rating scale, in either the "off" or "on" medication state, and no significant differences on non-motor symptoms, cognition, or quality-of-life measures either ([Stefanou et al., Therapeutic Advances in Neurological Disorders, 2026, PMID: 41631108](https://doi.org/10.1177/17562864251408269)). The one significant finding was an increased risk of weight loss in the GLP-1RA group — an expected effect of the drug class, not a PD-specific benefit. The honest summary: the biological rationale for GLP-1RAs in PD remains genuinely plausible and preclinical data remains encouraging, but the actual clinical trial evidence in real patients, at the scale that matters, has not confirmed a meaningful benefit so far. Researchers in this space are now specifically calling for brain-penetrant formulations and better patient-selection strategies in future trials — an acknowledgment that the current generation of GLP-1 drugs may simply not be reaching the brain effectively enough to test the hypothesis properly yet, not necessarily that the underlying biology is wrong. Testosterone Therapy and Parkinson's This is a smaller, older, but genuinely informative body of research. According to PubMed, the TEST-PD study — a double-masked, placebo-controlled randomized trial — gave men with Parkinson's disease and probable testosterone deficiency either testosterone therapy or placebo for 8 weeks ([Okun et al., Archives of Neurology, 2006, PMID: 16682542](https://doi.org/10.1001/archneur.63.5.729)). The primary outcome (a testosterone deficiency symptom scale) and the motor and non-motor PD measures showed no statistically significant difference between groups at 8 weeks. A few cognitive subscales did show improvement, and interestingly, men who continued testosterone therapy long-term in an open-label extension showed delayed but sustained improvement compared to those who didn't continue — though this was a small, non-randomized comparison at that stage, not the kind of evidence that confirms a real effect. The study's own authors were appropriately cautious in their conclusion, citing small sample size and short follow-up as real limitations, and explicitly recommended that practitioners weigh the risks and benefits carefully rather than treating testosterone as an established PD therapy based on this data. This remains a reasonable summary of where the evidence still stands today — a plausible area worth further research, not a confirmed treatment. Exercise, the Gym, and HIIT: The Strongest Lifestyle Evidence in This Whole Article This is where the evidence is genuinely the most encouraging, and specifically for higher-intensity exercise rather than moderate activity. According to PubMed, the SPARX trial — a Phase 2 randomized clinical trial in patients with early, untreated Parkinson's disease — compared high-intensity treadmill exercise (80-85% of maximum heart rate), moderate-intensity exercise (60-65% of max heart rate), and a wait-list control group over 6 months ([Schenkman et al., JAMA Neurology, 2018, PMID: 29228079](https://doi.org/10.1001/jamaneurol.2017.3517)). The high-intensity group showed essentially no worsening in motor symptom scores (change of 0.3 points) compared to meaningful worsening in the usual-care control group (change of 3.2 points) — and critically, only the high-intensity group, not the moderate-intensity group, reached the pre-specified threshold suggesting a real effect worth pursuing in a larger trial. The exercise was also found to be safe and feasible, without severe adverse musculoskeletal events, in patients recently diagnosed and not yet on medication. This is a genuinely important, intensity-specific finding: it wasn't "exercise helps," it was specifically high-intensity exercise showing a signal that moderate-intensity exercise didn't reach in the same trial. The authors were clear that a full efficacy trial was still needed to confirm meaningful clinical benefit, but this remains one of the most encouraging non-pharmacological findings in the entire PD research landscape. Body Fat, Inflammation, and Parkinson's: A More Complicated Story Than "Lose Fat to Fight Inflammation" This is worth treating carefully, because the honest research doesn't support a simple version of this idea, and it actually points in two different directions depending on the question being asked. For the question of developing PD in the first place: According to PubMed, a large Finnish prospective cohort study following over 45,000 people for an average of 18.8 years found a graded, dose-dependent relationship between higher midlife BMI and increased risk of developing Parkinson's disease later, independent of smoking, activity level, and other risk factors ([Hu et al., Neurology, 2006, PMID: 17159100](https://doi.org/10.1212/01.wnl.0000247052.18422.e5)). This does support the idea that midlife obesity is a real, independent risk factor for eventually developing PD — a genuine argument for maintaining healthy body composition well before any diagnosis. But for someone who already has Parkinson's, the research points somewhere more complicated. According to PubMed, a study comparing PD patients to matched controls found PD patients actually had lower body fat percentage and fat mass index than controls, not higher — and reduced whole-body fat percentage was specifically associated with higher inflammatory markers and higher risk of motor complications, not lower ([Tan et al., Parkinsonism & Related Disorders, 2018, PMID: 29914840](https://doi.org/10.1016/j.parkreldis.2018.06.020)). The same study found a notably higher prevalence of frailty in PD patients compared to controls. This is the opposite pattern from what "losing body fat reduces inflammation" would predict once someone already has the disease — in existing PD patients, lower fat mass tracked with worse inflammatory and functional markers, likely reflecting the frailty and unintentional weight loss that often accompanies disease progression, not a therapeutic target to pursue. The honest synthesis: midlife obesity appears to be a real, independent risk factor for developing PD in the first place, which is a legitimate argument for maintaining healthy body composition as a preventive measure. But once someone already has PD, aggressively pursuing further fat loss isn't supported by this research and may track with worse outcomes rather than better ones — the relationship between body composition and inflammation clearly changes once the disease is already present, and shouldn't be assumed to run in the same direction as it does for prevention. The Bottom Line Parkinson's disease has a genuinely expanding FDA-approved treatment landscape, including real innovations in the last two years like continuous infusion therapies. No peptide is currently FDA-approved for PD specifically, and GLP-1 receptor agonists — despite strong preclinical promise and real mechanistic plausibility — have not shown a clinical benefit in the largest, most rigorous trials conducted so far, though research into better brain-penetrant versions continues. Testosterone therapy has a small, methodologically limited, genuinely inconclusive evidence base — worth further research, not an established treatment. High-intensity exercise has the most encouraging signal of anything covered here, with real Phase 2 trial data specifically favoring high intensity over moderate intensity. And the body fat and inflammation question honestly runs in two different directions depending on whether you're asking about prevention (where midlife obesity is a real risk factor) or management after diagnosis (where lower body fat has tracked with worse markers, not better ones) — a distinction worth knowing rather than assuming "less fat is always better" applies the same way in both contexts.